Table 2.
Changes in lipid and free proprotein convertase subtilisin/kexin type 9 gene parameters at week 24 (intention-to-treat population)
| Parameter | Lerodalcibep (n = 319) |
Placebo (n = 159) |
Placebo adjusted |
P value |
|---|---|---|---|---|
| LDL-C (calculated)a | −50.5% | +8.1% | −58.6% | <.0001 |
| LDL-C (UC) | −47.9% | +8.1% | −56.0% | <.0001 |
| Total cholesterol | −32.8% | +4.9% | −37.7% | <.0001 |
| Apolipoprotein B | −38.9% | +6.7% | −45.6% | <.0001 |
| Non-HDL-C | −45.2% | +7.5% | −52.6% | <.0001 |
| VLDL cholesterol | −16.2% | +9.4% | −25.6% | <.0001 |
| Triglyceride (median) | −10.4% | +2.2% | −12.2% | <.0001 |
| Lp(a) (median) | −24.4% | −1.4% | −23.9% | <.0001 |
| HDL-C | +8.2% | +3.3% | +4.8% | <.01 |
| Free PCSK9 (median) | −94.3% | - | - | <.0001b |
Calculated using the Friedewald formula (Haase and Goldberg15).
P values evaluate the percentage change from baseline within the lerodalcibep group. All other P values are for the comparison with placebo.